Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 1/1998

01-02-1998 | Original Article

Preliminary study on the optimal dosage schedule for oral tegafur/uracil (UFT) chemotherapy

Authors: Sotaro Sadahiro, Masaya Mukai, Nobuhiro Tokunaga, Tomoo Tajima, Hiroyasu Makuuchi, Masahiko Yoshida, Hiroyuki Okabe, Junji Uchida, Setsuo Takeda, Norio Unemi

Published in: International Journal of Clinical Oncology | Issue 1/1998

Login to get access
Metadata
Title
Preliminary study on the optimal dosage schedule for oral tegafur/uracil (UFT) chemotherapy
Authors
Sotaro Sadahiro
Masaya Mukai
Nobuhiro Tokunaga
Tomoo Tajima
Hiroyasu Makuuchi
Masahiko Yoshida
Hiroyuki Okabe
Junji Uchida
Setsuo Takeda
Norio Unemi
Publication date
01-02-1998
Publisher
Springer-Verlag
Published in
International Journal of Clinical Oncology / Issue 1/1998
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/BF02490095

Other articles of this Issue 1/1998

International Journal of Clinical Oncology 1/1998 Go to the issue

Original Article

Radiation therapy for bone metastasis of hepatocellular carcinoma

Editorial

The necessity of a comprehensive system of education for clinical oncologists in Japan

Case Report

A case of ovarian endometrioid adenofibroma of borderline malignancy: Evidence for estrogen-producing tumor

Original Article

Prognostic value of pretreatment serum carcinoembryonic antigen and squamous cell carcinoma antigen levels for patients with stage I–III non-small cell lung cancer treated with radiation therapy alone

Original Article

Detection of known missense mutation ofhMLH1 in a hereditary non-polyposis colorectal cancer family using DNA extracts from mouthwash samples

Original Article

Response of the primary lesion in gastric cancer to chemotherapeutic trials
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits